ClinicalTrials.gg
Active, not recruitingNCT01918683Updated Jan 29, 2026

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients

An interventional study of TACE transarterial chemoembolization and stereotatic body radiotherapy (SBRT) in Hepatocellular Carcinoma, sponsored by Abramson Cancer Center at Penn Medicine. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Abramson Cancer Center at Penn Medicine · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Carcinoma, Hepatocellular by Abramson Cancer Center at Penn Medicine — 2 open to participants now, 4 under way, none of them phase 3. Carcinoma, Hepatocellular · Abramson Cancer Center at Penn Medicine.

Started
2013
with 1 other
No phase
2 of 10
none open now
Registered
3rd of 10
by date

Among the 10 studies in Carcinoma, Hepatocellular by Abramson Cancer Center at Penn Medicine, this one is one of 2 that started in 2013, is one of 2 with no phase, and was the 3rd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

2 of the 10 studies in Carcinoma, Hepatocellular by Abramson Cancer Center at Penn Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Carcinoma, Hepatocellular by Abramson Cancer Center at Penn Medicine, or all of them as a file.
02

Study summary

This trial is designed to be the initial prospective pilot investigation of the effectiveness of combined SBRT and TACE as bridging therapy for HCC patients awaiting liver transplanation. No prospective clinical trials regarding the combination of TACE and SBRT in pre-transplant population have been performed. We propose the trial be conducted as a pilot clinical trial with the goal of enrolling 40 patients into each arm

Read the detailed description

The purpose of this study is to determine whether the combination of stereotatic body radiotherapy (SBRT) tand transarterial chemoembolization (TACE) is an effective "bridging therapy" for patients hepatocellular carcinoma (HCC) of the liver awaiting transplantation.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient capable of giving
  • Patient diagnosed with hepatocellular carcinoma and listed or recommended to be listed for orthotopic liver transplantation at the participating institution
  • Age > 18 years old
  • Meets clinical criteria for eligibility for TACE to the target lesion per Interventional Radiology
  • Childs' Class A or B7
  • Eastern Clinical Oncology Group performance status 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Prior radiotherapy to the upper abdomen or radioembolization of the liver
  • Prior TACE to the target lesion, RFA, or liver transplant
  • Active GI bleed within 2 weeks of study enrollment
  • Active GI ulcer disease within 4 weeks of study enrollment
  • Ascites to medical therapy
  • to receiving radiotherapy or TACE
  • Complete obstruction of portal venous flow to the segment of liver that includes the target lesion
  • Contraindication to both contrast enhanced MRI and contrast enhanced CT (i.e. unable to undergo follow-up imaging or SBRT treatment planning)
  • Women who are pregnant
  • Participation in another concurrent treatment protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Other
    A -Tace alone

    A - TACE alone (control group, current practice and treatment)

    Radiation: TACE transarterial chemoembolization

  • Experimental
    B - Tace combined with SBRT

    B- TACE combined with SBRT (experimental group).

    Radiation: TACE transarterial chemoembolization · Radiation: stereotatic body radiotherapy (SBRT)

Interventions

  • RadiationTACE transarterial chemoembolization
  • Radiationstereotatic body radiotherapy (SBRT)
06

What researchers measure

Primary outcomes

  1. Progression Free Survival

    endpoint is OLT

    Time frame: 10 days

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Dec 2026 and a completion of Dec 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2013
First posted
Aug 8, 2013
Start
Jul 2013
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01918683
Responsible party
Sponsor
First posted
Aug 8, 2013
Start date
Jul 2013
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jan 29, 2026

Study contacts

Edgar Ben-Josef, MD
principal investigator · Abramson Cancer Center at Penn Medicine
Tarita Thomas, MD, PhD
principal investigator · Loyola University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion